Radwan S. Ajlan, MBBCh, FRCS(C), FICO, DABO, FASRS

Professional Background

Dr. Ajlan received his M.B., B.Ch. (Bachelor of Medicine, Bachelor of Surgery, from the Faculty of Medicine at Cairo University. He earned his Specialist in Ophthalmology certificate from McGill University, Royal College of Physicians and Surgeons of Canada and his FRCS(C) from the Royal College of Surgeons of Canada. He interned at the Faculty of Medicine Affiliate Hospital of Cairo University and completed residencies at King Abdul Aziz University's Department of Ophthalmology and McGill University's Department of Ophthalmology. His Medical Retina Fellowship was at Harvard Medical School, Beetham Eye Institute, Joslin Diabetes Center, Department of Ophthalmology and Surgical Retina Fellowship was at the University of Montreal, Department of Ophthalmology. His thirst for knowledge remains and he has gone on to study Applied Biostatistics, as well as take courses on funding research through the National Institute of Health and effective writing for healthcare at Harvard Catalyst, Harvard Medical School of Harvard University.

• MBChB, Bachelor of Medicine, Bachelor of Surgery, Cairo University
• Internship, Transitional medicine, Faculty of Medicine Affiliate Hospital, Cairo University
• Other, Ophthalmology, King Abdulaziz University, Department of Ophthalmology
• Residency, Ophthalmology , McGill University, Department of Ophthalmology
• Clinical Fellowship, Medical Retina, Beetham Eye Institute, Joslin Diabetes Center, Harvard Medical School
• Clinical Fellowship, Surgical and medical Retina, University of Montreal, Department of Ophthalmology

• Board Certified, American Board of Ophthalmology
• BPOA, Pennsylvania
• DEA, Drug Enforcement Agency
• KBHA, Kansas Board of Healing Arts
• Licentiate of the Medical Council of Canada LMCC, Medical Council of Canada
• NYOP, New York Office of Professions

• American Society of Retinal Specialists, Fellow of the ASRS (FASRS), 2022 - Present
• Association for Research in Vision and Ophthalmology, Professional Development and Education Committee (PDEC), Member, 2020 - 2023
• American Academy of Ophthalmology, Laser and Light Safety Working Group, Member, 2019 - Present
• American Society of Retinal Specialists, CME reviewer, ASRS Annual Meeting , Member, 2019 - 2020
• University of Kansas, Medical Staff Affairs, Physicians Round Table, Member, 2019 - 2019
• Kansas City Society of Ophthalmology and Otolaryngology, Member, 2018 - Present
• University of Kansas Health System, Pharmacy and Therapeutic Committee, Member, 2018 - Present

---

Research

Overview

Dr. Ajlan is the Department of Ophthalmology's Director of Research and is a Site Principal Investigator (PI) on five clinical trials, as well as a co- and sub-investigator on numerous studies both within the University of Kansas and in collaboration with other institutions. He is an active mentor and initiated an honors research mentorship for medical students. He recently developed an international council of ophthalmology sponsored retina fellowship and is pursuing funding to start a conventional retina fellowship program.

• GCT1015-05 - Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer, University of Kansas Department of Ophthalmology, Sub-Investigator
• 17403 - Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma, University of Kansas Department of Ophthalmology, Sub-Investigator
• 205678 - A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody, University of Kansas Department of Ophthalmology, Sub-Investigator
• FPA144-004 - A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT), University of Kansas Department of Ophthalmology, Sub-Investigator
• Array 818-302 (BEACON) – A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5- FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafaneib + Binimetinib + Cetuximb in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer, University of Kansas Department of Ophthalmology
• ASG-22CE-13-2 (Agensys)- Escalating doses of ASG-22CE in subjects with met urothelial cancer, University of Kansas Department of Ophthalmology
• EFC15392 - Multicenter, randomized, double-blind, placebocontrolled two stage study to characterize the efficacy, safety, tolerability and pharmacokinetics of Venglustat in patients at risk of rapidly progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD), University of Kansas, Department of Ophthalmology, Sub-Investigator
• 17403 - Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma, University of Kansas Department of Ophthalmology, Sub-Investigator
• EAY131: Molecular Analysis for Therapy Choice (MATCH). National Cancer Institute- (NCI-CIRB), University of Kansas, Department of Ophthalmology
• C-145-03 - Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck, University of Kansas Department of Ophthalmology, Sub-Investigator
• DRCR network research,, NIH funding support, PI